WallStSmart
ACRS

Aclaris Therapeutics Inc

NASDAQ: ACRS · HEALTHCARE · BIOTECHNOLOGY

$4.47
+5.92% today

Updated 2026-04-29

Market cap
$624.30M
P/E ratio
P/S ratio
79.77x
EPS (TTM)
$-0.53
Dividend yield
52W range
$1 – $5
Volume
2.0M

Aclaris Therapeutics Inc (ACRS) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+16.7%
Last 4 quarters
Revenue YoY growth
-85.9%
Most recent quarter
EPS YoY growth
+84.2%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+2.1%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+2.7%
2025-11-06
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-03$-0.16-6.7%$3.05$3.10+1.6%
2025-11-06$-0.12+7.7%$2.26$2.32+2.7%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.15$-0.16-6.7%$1.29M-85.9%
2025-09-30$-0.13$-0.12+7.7%$3.30M-24.1%
2025-06-30$-0.14$-0.13+7.1%$1.78M-35.8%
2025-03-31$-0.29$-0.12+58.6%$1.46M-39.3%
2024-12-31$-0.38$-1.01-169.3%$9.21M-47.6%
2024-09-30$-0.01$-0.11-1000.0%$4.35M-53.2%
2024-06-30$-0.20$-0.15+25.0%$2.77M+48.0%
2024-03-31$-0.29$-0.24+17.2%$2.40M-5.1%
2023-12-31$-0.34$-0.02+94.1%$17.57M
2023-09-30$-0.48$-0.41+14.6%$9.28M
2023-06-30$-0.45$-0.42+6.7%$1.87M
2023-03-31$-0.44$-0.40+9.1%$2.53M

Frequently asked questions

Has Aclaris Therapeutics Inc beaten earnings estimates?
Aclaris Therapeutics Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +16.7% over the last 4 quarters.
How does ACRS stock react to earnings?
ACRS stock has moved an average of +2.1% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.
What is Aclaris Therapeutics Inc's revenue growth rate?
Aclaris Therapeutics Inc reported year-over-year revenue growth of -85.9% in its most recent quarter, with EPS growing +84.2% year-over-year.